Behind the apparent simplicity of ABiC™ and Canaloplasty is the iTrack™ surgical system. Intelligently designed and meticulously tested across each treatment step, the iTrack™ surgical system comprises the iTrack™ microcatheter, the ViscoInjector™ viscoelastic injector, and the iLumin™ illumination source.
Featuring a unique, proprietary illuminated tip, you can monitor progress of the iTrack™ microcatheter through every procedural step. iTrack’s tip is also lubricious and atraumatic, which means that ease of insertion is enhanced, and direction accuracy is maximized to prevent the catheter broaching the collector channel ostia.
An internal guide wire within iTrack™ provides excellent tactile feedback as the tip is advanced, offering a vital insight on whether the canal is tight, grainy, or completely open.
The ViscoInjector™, which attaches to the iTrack™ microcatheter, is manually operated using a tactile and audible knob to release a precisely measured aliquot of viscoelastic per click.
The delivery of viscoelastic during the withdrawal of iTrack™ from Schlemm’s canal accomplishes a vital additional function that complements the mechanical opening achieved with the iTrack™ microcatheter; it separates the compressed tissue planes of the trabecular meshwork, causing any herniated inner wall tissue to withdraw from the collector channels.
ABiC™ is a comprehensive minimally invasive glaucoma surgery procedure that flushes out the natural outflow channels without damaging tissue, and without leaving behind a stent or shunt. Designed to re-establish the eye’s natural outflow drainage system, ABiC™ accesses, catheterizes, and viscodilates the trabecular meshwork, Schlemm’s canal, and also the distal outflow system— maximizing efficacy and minimizing tissue trauma. On average, ABiC™ performed with the iTrack™ surgical system achieves a reduction in mean IOP of 30%, combined with a 50% reduction in medication dependence.1
Clinical studies show that Canaloplasty performed with the iTrack™ surgical system reduces IOP significantly and durably — without the risks and discomfort associated with trabeculectomy.2 This means that the treatment can be offered earlier in the disease.
In addition, Canaloplasty doesn’t produce a filtering bleb, and hence patients can resume day-to-day activities directly following treatment with minimal follow-up required.
1. 228-eye ABiC 12-Month Case Series Data, presented at ASCRS 2016. Data on file. Ellex Medical.
2. Lewis RA, von Wolff K, Tetz M, et al. Canaloplasty: three-year results of circumferential viscodilation and tensioning of Schlemm’s canal using a microcatheter to treat open-angle glaucoma. J Cataract Refract. Surg. 2011(37):682-690.
Illuminated fiber optic tip provides continuous location feedback, eliminating misdirection into a suprachoroidal drainage system or the collector channel ostia.
Internal guide wire enables you to push through herniations and to maneuver through tight areas or structures of the canal, without the risk of creating an artificial pathway.
Sophisticated injector releases a precise dose of viscoelastic to balloon open the canal and the collector channel ostia.
Watch the iTrack™ as it circumnavigates Schlemm’s, separating the herniations of the meshwork into the collector channels and breaking inner lumen adhesions.
In this video Mahmoud A. Khaimi, MD (USA) demonstrates restoration of the natural outflow pathway with ABiC™.
In this video interview, glaucoma expert Mahmoud A. Khaimi, MD (USA), describes the advent of ABiC™ performed with the iTrack™ surgical system.
